Crohn's Disease Drug Fails Phase III Trial

The first of four phase III studies investigating vercirnon , an investigational chemokine receptor 9 antagonist, in adult patients with moderately to severely active Crohn's disease did not achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission.


More...